{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:49:34Z","timestamp":1792651774768,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.omtm.2021.06.007","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T08:58:30Z","timestamp":1624525110000},"page":"107-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Efficacious, safe, and stable inhibition of corneal neovascularization by AAV-vectored anti-VEGF therapeutics"],"prefix":"10.1016","volume":"22","author":[{"given":"Wenqi","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip W.L.","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihye","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2021.06.007_bib1","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jtos.2018.06.004","article-title":"Current and emerging therapies for corneal neovascularization","volume":"16","author":"Roshandel","year":"2018","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.omtm.2021.06.007_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","article-title":"Ocular neovascularization: an epidemiologic review","volume":"43","author":"Lee","year":"1998","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.omtm.2021.06.007_bib3","first-page":"627674","article-title":"Anti-VEGF Therapy and the Retina: An Update","volume":"2015","author":"Tah","year":"2015","journal-title":"J.\u00a0Ophthalmol."},{"key":"10.1016\/j.omtm.2021.06.007_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.omtm.2021.06.007_bib5","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/ICO.0b013e31823f8d71","article-title":"Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study","volume":"31","author":"Benayoun","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.omtm.2021.06.007_bib6","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1167\/iovs.09-3745","article-title":"Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival","volume":"51","author":"Dastjerdi","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2021.06.007_bib7","doi-asserted-by":"crossref","first-page":"7376","DOI":"10.1167\/iovs.14-15257","article-title":"Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization","volume":"55","author":"Kim","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2021.06.007_bib8","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/ICO.0b013e3181d92834","article-title":"Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty","volume":"29","author":"Foroutan","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.omtm.2021.06.007_bib9","doi-asserted-by":"crossref","first-page":"e94205","DOI":"10.1371\/journal.pone.0094205","article-title":"Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2021.06.007_bib10","doi-asserted-by":"crossref","first-page":"17576","DOI":"10.1038\/s41598-019-54171-5","article-title":"Optical Coherence Tomography Angiography Imaging to monitor Anti-VEGF treatment of Corneal Vascularization in a Rabbit Model","volume":"9","author":"Devarajan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2021.06.007_bib11","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e3182775f8d","article-title":"Topical ranibizumab as a treatment of corneal neovascularization","volume":"32","author":"Ferrari","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.omtm.2021.06.007_bib12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/ICL.0000000000000709","article-title":"Subconjunctival Aflibercept for the Treatment of Formed Corneal Neovascularization","volume":"47","author":"Sella","year":"2021","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.omtm.2021.06.007_bib13","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.omtm.2021.06.007_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40662-017-0094-6","article-title":"Therapeutic approaches for corneal neovascularization","volume":"4","author":"Feizi","year":"2017","journal-title":"Eye Vis. (Lond.)"},{"key":"10.1016\/j.omtm.2021.06.007_bib15","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.omtm.2021.06.007_bib16","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/gt.2008.66","article-title":"AAV-mediated gene therapy for retinal disorders: from mouse to man","volume":"15","author":"Buch","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2021.06.007_bib17","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1089\/hum.2010.041","article-title":"Ocular gene therapy: an evaluation of recombinant adeno-associated virus-mediated gene therapy interventions for the treatment of ocular disease","volume":"21","author":"Roy","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.06.007_bib18","first-page":"67","article-title":"State-of-the-art human gene therapy: part I. Gene delivery technologies","volume":"18","author":"Wang","year":"2014","journal-title":"Discov. Med."},{"key":"10.1016\/j.omtm.2021.06.007_bib19","first-page":"151","article-title":"State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications","volume":"18","author":"Wang","year":"2014","journal-title":"Discov. Med."},{"key":"10.1016\/j.omtm.2021.06.007_bib20","doi-asserted-by":"crossref","first-page":"e70544","DOI":"10.1371\/journal.pone.0070544","article-title":"Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in\u00a0vivo","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2021.06.007_bib21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ajo.2018.08.026","article-title":"Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study","volume":"197","author":"Liu","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2021.06.007_bib22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12886-017-0554-8","article-title":"Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study","volume":"17","author":"Xu","year":"2017","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.omtm.2021.06.007_bib23","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1097\/IAE.0000000000001763","article-title":"Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity","volume":"38","author":"Jin","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.omtm.2021.06.007_bib24","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1097\/IAE.0000000000001404","article-title":"Efficacy and safety of intravitreal conbercept injections in macular edema secondary to retinal vein occlusion","volume":"37","author":"Sun","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.omtm.2021.06.007_bib25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000353437","article-title":"KH902, a recombinant human VEGF receptor fusion protein, reduced the level of placental growth factor in alkali burn induced-corneal neovascularization","volume":"50","author":"Zhou","year":"2013","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.omtm.2021.06.007_bib26","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.4103\/ijo.IJO_339_17","article-title":"The inhibitory effect of different concentrations of KH902 eye drops on corneal neovascularization induced by alkali burn","volume":"65","author":"Wu","year":"2017","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.omtm.2021.06.007_bib27","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.2147\/OPTH.S260302","article-title":"Effects of VEGF Inhibitor Conbercept on Corneal Neovascularization Following Penetrating Keratoplasty in Rabbit Model","volume":"14","author":"Liu","year":"2020","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.omtm.2021.06.007_bib28","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3390\/pharmaceutics12080767","article-title":"Adeno-Associated Virus Mediated Gene Therapy for Corneal Diseases","volume":"12","author":"Bastola","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtm.2021.06.007_bib29","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41434-018-0035-6","article-title":"Serotype survey of AAV gene delivery via subconjunctival injection in mice","volume":"25","author":"Song","year":"2018","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2021.06.007_bib30","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1167\/iovs.02-0641","article-title":"Central corneal thickness in Latinos","volume":"44","author":"Hahn","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2021.06.007_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.survophthal.2017.12.008","article-title":"Angiogenesis and lymphangiogenesis in corneal transplantation-A review","volume":"63","author":"Zhong","year":"2018","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.omtm.2021.06.007_bib32","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1172\/JCI20465","article-title":"VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment","volume":"113","author":"Cursiefen","year":"2004","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2021.06.007_bib33","doi-asserted-by":"crossref","first-page":"a006569","DOI":"10.1101\/cshperspect.a006569","article-title":"VEGF and Notch in tip and stalk cell selection","volume":"3","author":"Blanco","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.omtm.2021.06.007_bib34","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature05571","article-title":"Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis","volume":"445","author":"Hellstr\u00f6m","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2021.06.007_bib35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12079-016-0352-8","article-title":"VEGF-A\/VEGFR2 signaling network in endothelial cells relevant to angiogenesis","volume":"10","author":"Abhinand","year":"2016","journal-title":"J.\u00a0Cell Commun. Signal."},{"key":"10.1016\/j.omtm.2021.06.007_bib36","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/CIRCRESAHA.116.302953","article-title":"Molecular controls of arterial morphogenesis","volume":"116","author":"Simons","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.omtm.2021.06.007_bib37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jtos.2016.09.002","article-title":"Current and Upcoming Therapies for Ocular Surface Chemical Injuries","volume":"15","author":"Baradaran-Rafii","year":"2017","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.omtm.2021.06.007_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/tvst.7.5.15","article-title":"Functional Staging of Corneal Neovascularization Using Fluorescein and Indocyanine Green Angiography","volume":"7","author":"Palme","year":"2018","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.omtm.2021.06.007_bib39","doi-asserted-by":"crossref","first-page":"356","DOI":"10.18240\/ijo.2020.02.22","article-title":"Complications of intrastromal bevacizumab injection in lamellar keratoplasty","volume":"13","author":"Soleimani","year":"2020","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2021.06.007_bib40","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ophtha.2010.08.008","article-title":"A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration","volume":"118","author":"Zhang","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtm.2021.06.007_bib41","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.omtm.2020.06.007","article-title":"Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD","volume":"18","author":"Kiss","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2021.06.007_bib42","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1167\/tvst.10.1.34","article-title":"Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates","volume":"10","author":"Kiss","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.omtm.2021.06.007_bib43","doi-asserted-by":"crossref","first-page":"e26432","DOI":"10.1371\/journal.pone.0026432","article-title":"Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in\u00a0vivo","volume":"6","author":"Mohan","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2021.06.007_bib44","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtn.2017.12.019","article-title":"Transcriptome Profiling of Neovascularized Corneas Reveals miR-204 as a Multi-target Biotherapy Deliverable by rAAVs","volume":"10","author":"Lu","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2021.06.007_bib45","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/sj.gt.3301695","article-title":"Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy","volume":"9","author":"Lai","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2021.06.007_bib46","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11373-007-9153-7","article-title":"Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model","volume":"14","author":"Lai","year":"2007","journal-title":"J.\u00a0Biomed. Sci."},{"key":"10.1016\/j.omtm.2021.06.007_bib47","doi-asserted-by":"crossref","first-page":"17840","DOI":"10.1038\/s41598-017-18002-9","article-title":"AAV vector-meditated expression of HLA-G reduces injury-induced corneal vascularization, immune cell infiltration, and fibrosis","volume":"7","author":"Hirsch","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2021.06.007_bib48","first-page":"2344","article-title":"Subconjunctival injection of recombinant AAV-angiostatin ameliorates alkali burn induced corneal angiogenesis","volume":"13","author":"Cheng","year":"2007","journal-title":"Mol. Vis."},{"key":"10.1016\/j.omtm.2021.06.007_bib49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10456-007-9074-0","article-title":"Angiogenesis and chronic inflammation: cause or consequence?","volume":"10","author":"Costa","year":"2007","journal-title":"Angiogenesis"},{"key":"10.1016\/j.omtm.2021.06.007_bib50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-0716-0599-8_7","article-title":"Preparation and Administration of Adeno-associated Virus Vectors for Corneal Gene Delivery","volume":"2145","author":"Song","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtm.2021.06.007_bib51","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/02713683.2013.779720","article-title":"Direct comparison of administration routes for AAV8-mediated ocular gene therapy","volume":"38","author":"Igarashi","year":"2013","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.omtm.2021.06.007_bib52","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ymthe.2020.04.004","article-title":"Intrastromal Gene Therapy Prevents and Reverses Advanced Corneal Clouding in a Canine Model of Mucopolysaccharidosis I","volume":"28","author":"Miyadera","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.06.007_bib53","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ymthe.2020.01.007","article-title":"Encouraging and Unsettling Findings in Long-Term Follow-up of AAV Gene Transfer","volume":"28","author":"Herzog","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.06.007_bib54","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.ymthe.2019.10.005","article-title":"Liver Gene Therapy: Reliable and Durable?","volume":"27","author":"Herzog","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.06.007_bib55","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2021.06.007_bib56","doi-asserted-by":"crossref","first-page":"e35318","DOI":"10.1371\/journal.pone.0035318","article-title":"Corneal transduction by intra-stromal injection of AAV vectors in\u00a0vivo in the mouse and ex\u00a0vivo in human explants","volume":"7","author":"Hippert","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2021.06.007_bib57","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/978-3-642-30406-4_19","article-title":"Stem cells and corneal epithelial maintenance: insights from the mouse and other animal models","volume":"55","author":"Mort","year":"2012","journal-title":"Results Probl. Cell Differ."},{"key":"10.1016\/j.omtm.2021.06.007_bib58","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.04.002","article-title":"Inflammation promotes the loss of adeno-associated virus-mediated transgene expression in mouse liver","volume":"141","author":"Breous","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omtm.2021.06.007_bib59","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1182\/blood-2004-03-0848","article-title":"Systemic protein delivery by muscle-gene transfer is limited by a local immune response","volume":"105","author":"Wang","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2021.06.007_bib60","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1387\/ijdb.103167dr","article-title":"The role of pericytes in angiogenesis","volume":"55","author":"Ribatti","year":"2011","journal-title":"Int. J. Dev. Biol."},{"key":"10.1016\/j.omtm.2021.06.007_bib61","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10456-018-9648-z","article-title":"Excess vascular endothelial growth factor-A disrupts pericyte recruitment during blood vessel formation","volume":"22","author":"Darden","year":"2019","journal-title":"Angiogenesis"},{"key":"10.1016\/j.omtm.2021.06.007_bib62","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bjo.87.1.101","article-title":"Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation","volume":"87","author":"Cursiefen","year":"2003","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2021.06.007_bib63","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/TP.0000000000000512","article-title":"VEGF-trap aflibercept significantly improves long-term graft survival in high-risk corneal transplantation","volume":"99","author":"Dohlman","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.omtm.2021.06.007_bib64","first-page":"783163","article-title":"Lymphatics and lymphangiogenesis in the eye","volume":"2012","author":"Nakao","year":"2012","journal-title":"J.\u00a0Ophthalmol."},{"key":"10.1016\/j.omtm.2021.06.007_bib65","doi-asserted-by":"crossref","first-page":"9828","DOI":"10.1128\/JVI.75.20.9828-9835.2001","article-title":"Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis","volume":"75","author":"Zheng","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2021.06.007_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/9780471729259.mc14d01s26","article-title":"Production and discovery of novel recombinant adeno-associated viral vectors","author":"Mueller","year":"2012","journal-title":"Curr. Protoc. Microbiol."},{"key":"10.1016\/j.omtm.2021.06.007_bib67","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1167\/iovs.19-27591","article-title":"Repeat Corneal Neovascularization is Characterized by More Aggressive Inflammation and Vessel Invasion Than in the Initial Phase","volume":"60","author":"Mukwaya","year":"2019","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2021.06.007_bib68","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.omtm.2018.09.003","article-title":"Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer","volume":"11","author":"Wang","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050121001091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050121001091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:26:32Z","timestamp":1762421192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050121001091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":68,"alternative-id":["S2329050121001091"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2021.06.007","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacious, safe, and stable inhibition of corneal neovascularization by AAV-vectored anti-VEGF therapeutics","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2021.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors.","name":"copyright","label":"Copyright"}]}}